42. Yogeshwar D, Anandita R, Bidisha G, Batra S, and Syal K (2024) COVID-19, Pneumonia and Tuberculosis: Crosstalk and Implications on Treatment (Under Revision)

41. Syal K. (2024) The Interplay of Tuberculosis and COVID-19: Insights into Global Health Challenges.

Journal of Biosciences (Springer Nature) Accepted

40. Neethu RS. Sinha KS, Pavan R, Batra S, and Syal K (2024) Promoter characterization of RelZ-bifunctional (pp)pGpp synthetase from mycobacteria.

Genes to Cells (Wiley) 

   39. Syal K. (2024) Evaluation of Interplay of Gene Expression and Chromosome Structure in E. coli Growth: Regulatory Insights.

Current Microbiology (Springer-Nature)

   38. Y Devarakonda, Achal DR, Anindita Ray, and Syal K (2024) Novel edible multi-epitope vaccine construct against Enterococcus faecalis.

The Nucleus (Springer-Nature)

2023 

37. S Sinha, RS Neethu, Devarakonda Y, Rathi A, Reddy RP, Batra S, Syal K.(2023) Tale of Twin Bifunctional Second Messenger (p)ppGpp Synthetases and their Function in Mycobacteria.

ACS Omega (ACS) 

36. Y Devarakonda, Reddi Lakshmi, Neethu RS, Mitul Bhalerao, Syal K. (2023) Second Messenger (p)ppGpp Mediated Biofilm Formation and Measurement Through Novel Chip Devices.

Miniatured Electrochemical Devices-Taylor & Francis- (Scopus Indexed-book chapter) 

35. Y Devarkonda, MVN J Reddy, Neethu RS, A Chandran andSyal K. (2023) Multi epitope vaccine candidate design against Streptococcus pneumonia. 

Journal of Biomolecular Structure and Dynamics (Taylor & Francis) (Impact Factor-5.3) 

 2022

34. Batra S, Nair,Syal K(2022) An unusual presentation of superior mensenteric venous occlusion in mild COVID19.  

IJCB (Springer-Nature). 
 
33. Neethu RS, Janaradhan MVN, Batra S, Srivastav S and Syal K. (2022) Vitamin C and its therapeutic potential in the management of COVID19. 

Clinical Nutrition (Elsevier, ESPEN Society). (Impact Factor-3.00) 

32. Syal K.(2022) Possibility of relapse of COVID19 in asymptomatic cases and risk assessment.

IJCB (Springer-Nature). (Impact Factor 2.22)
  

2021 

31. Syal K.*,Neethu RS, MVN Janaradhan Reddy The Extended (p)ppGpp family, New Dimensions in Stress response. 

Current Research in Microbial Sciences-Companion Title of Current Opinion in Microbiology (Elsevier) In Press. (Impact Factor 4.8)

30.  Syal K. (2021) Guidelines on newly identified limitations of diagnostic tools for COVID‐19 and consequences.

Journal of Medical Virology (Wiley). 2021;93(4):1837-42. (Impact Factor-20.693)

2020

29.  Kaur S, Yadav D, Singh S, Kumari M, Kumar D,Syal K, et al. (2020) Selocalcitol: Scope of inhalational formulation for prevention and cure of COVID-19 illness.

Research Square (Scopus-indexed)
 

29. Syal K.(2020) COVID‐19: Herd Immunity and Convalescent Plasma Transfer Therapy. 

Journal of Medical Virology (Wiley) (Impact Factor-20.693)

 Before Joining BITS-Pilani

2019

27. Nemec, Singh, Ali, Tseng,Syal Ket al. (2019) Novel CTD-kinases mediate gene-class specific regulation of RNA polymerase II

Nature Chemical Biology (NPG), 15, 123–131. (Impact Factor 16.2)

            Covered in News and Views of Nature Chemical Biology 

2018

26. Bhardwaj N*,Syal K*, and Chatterji. (2018) Role of omega subunit in bacterial stress response. 

Genes to Cells (Wiley) * 23 (5), 357-369 (Impact Factor-2.3)

*Equal Contribution.  

25. Syal Kand Chatterji D. (2018) Vitamin C: Inhibitor of Stress response and biofilm formation in mycobacteria. 

Adv Exp Med Biol (Springer-Nature) 321-332. (Impact Factor-3.65)

2017

24. Maiti K^#,Syal K^#,Chatterji D. and Jayaraman N. (2017) Synthetic Arabinomannan Heptasaccharide Glycolipids Inhibit Biofilm Growth and Supplements Isoniazid Effects in Mycobacterium smegmatis. 

Chembiochem- A European Journal of Chemical Biology (Wiley) 18(19), 1959–1970. (Impact Factor-3.46)

# Equal contribution.

23. Syal K*(2017)Novel method for quantitative estimation of biofilms. 

Current Microbiology (Springer Nature) 74, 1194-1199. * First and Corresponding (Impact Factor-2.34)

             On reviewer’s advice, named as “Syal method for biofilm quantification”. 

22. Syal K,Fentie K, Bhardwaj N, Maiti K, Jayaraman N, Stallings CL and Chatterji D. (2017) Synthetic (p)ppGpp analogue is an inhibitor of stringent response in mycobacteria.

Antimicrobial Agent and Chemotherapy (American Society for Microbiology) 61(6), e00443-17, 1-14.  (Impact Factor 5.93)

             Covered in Science Breakthrough Section of ‘The Hindu’ and ‘The Better India initiative’

21. Syal K, Bhardwaj N and Chatterji D. (2017) Vitamin C targets (p)ppGpp synthesis stalling longer term survival and biofilm formation in Mycobacterium smegmatis. 

FEMS Microbiology Letters (Oxford University Press), 364 (1), 1-7. (Impact Factor-2.8)

             Covered in Science Breakthrough Section of ‘The Hindu’ and ‘Research Matters’

2016

20. Syal K,Maiti K, Naresh K, Avaji PG, Chatterji D and Jayaraman N. (2016) Synthetic Arabinomannan Glycolipids impedes mycobacterial growth, sliding motility and biofilm formation. 

Glycoconjugate Journal (Springer Nature) 33 (5), 763–777. (Impact Factor-3.1)

             Covered by ‘The Times of India’ and ‘Deccan Herald’

               “Simple synthetic sugar molecules as antimicrobials”

19. Syal K^$(2016) BCG vaccine fails to prevent the reactivation of latent tuberculosis. 

Med Hypothesis (Elsevier) 88, 82-83. (Impact Factor-4.42)

$-First and Corresponding 

2015

18. Syal K, Joshi H, Jain V and Chatterji D. (2015) Novel pppGpp binding site at the C-terminal region of the Rel enzyme from Mycobacterium smegmatis. 

The FEBS Journal (Wiley) 282(19), 3773-3785. (Impact Factor 5.63)

             Covered by ‘The Hindu'

17. Syal Kand Chatterji D. (2015) Differential binding of ppGpp and pppGpp to RNA polymerase from E. coli: Photocrosslinking and Mass spectral studies. 

Genes to Cells (Wiley)20 (12), 1006-1016. (Impact Factor-2.3)

             ppGpp and pppGpp are different, and each of them could play different roles

16. 16. Syal K,Maiti K, Naresh K, Jayaraman N and Chatterji D. (2015) Synthetic Glycolipids and (p)ppGpp Analogs: Development of Inhibitors for Mycobacterial Growth, Biofilm and Stringent Response. 

Adv Exp Med & Biol (Springer Nature) 842, 309-327. (Impact Factor-3.65)

15. Syal K^$and Tadala R. (2015) Modifications in Trypsin Digestion Protocol for Increasing the Efficiency and Coverage. 

Protein and Peptide Letters (Bentham Science, Netherlands) 22(4) 372-378. $-First and Corresponding (Impact Factor-1.93)

             Editor’s Choice article & Indexed on Cover page 

14. Syal K, Chakraborty S, Bhattacharya R and Banerjee D. (2015) Combined inhalation and oral supplementation of Vitamin A: Potential new drug therapy for tuberculosis. 

Med Hypothesis (Elsevier) 84(3), 199-203. (Impact Factor-4.4)

             Animal trials confirmed this hypothesis. 

13. Chakraborty S, Bhattacharyya R,Syal Kand Banerjee D. (2015) Retinoic Acid and Iron Metabolism: A Step Towards Design of a Novel Antitubercular Drug.

Curr Pharma Biotech (Bentham Science, Netherlands) 15 (12), 1166-1172. (Impact Factor-2.8)

2014

12. Syal K^$(2014) Point of Care testing for measurement of white blood cell count and C-reactive protein levels in blood. 

Clin Chim Acta (Elsevier) 437, 218. (Impact Factor-6.32)

$-First and Corresponding 

11. Syal K^$,Srinivasan A and Banerjee D. (2014) Vitamin-D receptor, Vitamin-A receptor, Coronin-1 and Interferonγ levels in PBMCs of type-2 diabetes patients: Molecular link between Diabetes and Tuberculosis. 

IJCB (Springer Nature) 30(3), 323-328. $-First and Corresponding (Impact Factor-2.34)

10. Chakraborty S,Syal K,Bhattacharyya R and Banerjee D (2014).  Vitamin Deficiency and Tuberculosis: Need for Urgent Clinical Trial for Managment of Tuberculosis. 

J Nut Health 2(2): 1-6. (Impact Factor-2.6)

9. Syal K^$(2014) Comments on “Serum Urea: Albumin Ratio as a Prognostic Marker in Critical Patients with Non-chronic Kidney Disease”.

 IJCB (Springer Nature) 29 (3), 393.  (Impact Factor-2.34)

^$-First and Corresponding

8. Banerjee D^#,Syal K^#and Bhattacharya R^# (2014) cellfree DNA. Advances in Biochemistry and Biotechnology (Vol.2), 209-224 (^#Equal contribution)-Book Chapter

7. Banerjee D^#,Syal K^#, Nagpal N^#, Bhattacharya R^#(2014) Point of Care Testing. Advances in Biochemistry and Biotechnology (Vol.2), 225-239. (^#Equal contribution)- Book Chapter

2013

6. Srinivasan A,Syal K, Banerjee D, Hota D, Gupta D, Kaul D and Chakrabarti A (2013) Low plasma levels of cholecalciferol and 13-cis-retinoic acid in tuberculosis: Implications in host-based chemotherapy. 

Nutrition (Elsevier) 29, 1245-1251. (Impact Factor-4.9)

             Covered by Science alert

5. Syal K,Srinivasan A and Banerjee D (2013) Streptomycin interference in Jaffe reaction - Possible false positive creatinine estimation in excessive dose exposure. 

Clinical Biochemistry (Elsevier) 46, 177-179. (Impact Factor-3.63)

             Cover page (Indexed) 

             Referred by Sigma-Aldrich protocols and constitute the primary information on Jaffe reaction for creatinine determination.

4. Syal K^$,Banerjee D & Srinivasan A (2013) Creatinine Estimation and Interference. 

IJCB (Springer Nature) 28(2), 210-211. (Impact Factor-2.34)

^$-First and Corresponding 

2012

3. Syal Kand Karande AA (2012) IgG2 subclass isotype antibody and intrauterine infections. 

Current Science (Indian Academy of Science) 102, 1534-1539. (Impact Factor-1)

This review has been published from the PhD Course work (Subject: Immunology) 

             Cover Page Article 

2. Syal K^$and Banerjee  D. (2012) Theories of Immunosurveillance/Immunoevasion: An attempt to explain Persistence of Cancer. 

Journal of Pharmacy 2, 74-75.  (Impact factor-5.4)

^$-First and Corresponding 

1. Naresh K, Avaji PG, Maiti K, Bharati BK,Syal K,Chatterji D and Jayaraman N (2012) Synthesis of β-arabinofuranoside glycolipids, studies of their binding to surfactant protein-A and effect on sliding motilities of M. smegmatis. 

Glycoconjugate Journal (Springer Nature) 29, 107-118 (Impact Factor 3.1).

Popular Science Articles

2.  Syal K. Mitochondria as Friend or Foe. Fingerprints (JNCASR Megazine)

1.   Syal K. Antiretroviral Therapy.Microcosmos (Delhi University)